InsiderTrades

Form 4 for IBRX ImmunityBio, Inc.

Accepted 2024-02-02 00:00:00 ET · period of report 2024-01-31 · accession 0001326110-24-000013 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-02 2024-01-31 IBRX LAUER REGAN J CAO F - Tax $3.36 -13.5K 94.3K -12% -$45.3K
D 2024-02-02 2024-01-31 IBRX LAUER REGAN J CAO M - OptEx $0.00 +32.9K 107.8K +44% $0
D 2024-02-02 2024-01-31 IBRX LAUER REGAN J CAO M - OptEx $0.00 -32.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-31 F D 13,470 $3.36 94,334 D — —
2 Common Common Stock 2024-01-31 M A 32,872 $0.00 107,804 D — —
3 Derivative Restricted Stock Units 2024-01-31 M D 32,872 $0.00 0 D — · — to — 32,872 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.